RCS - GenIP PLC - Contract Win

GenipAnnouncement

26/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ1420Ca&default-theme=true

RNS Number : 1420C  GenIP PLC  26 March 2025

 

 

26 March 2025

 

GenIP Plc

("GenIP" or the "Company")

 

Contract Win

 

GenIP Plc, a technology business providing Generative Artificial Intelligence
(GenAI) services to help research organisations and corporations commercialise
their innovations, is pleased to announce it has secured a contract worth
approximately USD$65,000 with a Singapore-based research institute (the
"Client").

 

This contract, covering the delivery of 100 GenAI-enhanced analytical
assessments, is part of a wider bid process with leading Asian institutions
referred to in GenIP's announcement 13 March 2025.

 

The award results from GenIP's ongoing sponsorship of key technology transfer
initiatives and marketing activities in leading Southeast Asian technology
hubs.

 

Analytical assessment revenue will be recognised upon report production by
GenIP and delivery to the Client.

 

Melissa Cruz, CEO of GenIP, commented:

 

"We are delighted to partner with a leading research and innovation
institution in Singapore to accelerate the commercialisation of new
technological discoveries. This collaboration demonstrates the broad
application of our technology evaluation services by supporting cutting-edge
clinical and healthcare research and innovation. Furthermore, this contract
underscores the significant size of the addressable market for our technology
commercialisation services."

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                  Via Redchurch Communications

 Melissa Cruz, CEO

 Redchurch Communications (Financial PR)    genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUVVWRVKUOUAR